Wedbush Thinks Miragen Therapeutics Inc’s Stock is Going to Recover

By Austin Angelo

Wedbush analyst Liana Moussatos reiterated a Buy rating on Miragen Therapeutics Inc (NASDAQ: MGEN) today and set a price target of $19. The company’s shares closed yesterday at $6.29, close to its 52-week low of $5.01.

According to, Moussatos is a 3-star analyst with an average return of 2.4% and a 42.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Catabasis Pharmaceuticals, and Global Blood Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Miragen Therapeutics Inc with a $18.83 average price target, representing a 199.4% upside. In a report issued on August 6, Oppenheimer also assigned a Buy rating to the stock with a $19 price target.


See today’s analyst top recommended stocks >>

Based on Miragen Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.66 million. In comparison, last year the company had a GAAP net loss of $7.31 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Miragen Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates, MRG-106 focuses on the treatment of cancer; and MRG-201 deals with the treatment of pathological fibrosis.